Skip to main content

Study Looks at COVID Threat to Folks With Weakened Immune Systems

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 29, 2024.

By Dennis Thompson HealthDay Reporter

MONDAY, Jan. 29, 2024 -- It’s long been known that people with immune deficiencies are at increased risk for severe COVID.

But a new study shows the threat varies dramatically based on how severe that immune suppression is and the reason behind it, researchers report in the Jan. 24 issue of the journal Science Translational Medicine.

People suffering immune compromise due to a blood cancer or an organ transplant were most likely to have a prolonged bout of severe COVID, researchers found.

On the other hand, patients with mild immune compromise -- such as those with an autoimmune disease taking anti-inflammatory anti-tumor necrosis factor (TNF) drugs -- tended to have COVID experiences similar to people with normal immune systems.

Meanwhile, patients with immune compromise from deficient B-cell levels had a moderate risk of severe COVID. B-cells protect people from infection by producing antibodies.

“While our sample size is limited, these results provide reassurance that most patients with mild/moderate immunosuppression will be able to clear the virus during the acute phase of infection,” said researcher Dr. Jonathan Li, an infectious disease doctor at Brigham and Women’s Hospital in Boston.

For the study, Li and colleagues studied a group of 56 immunocompromised patients, comparing them to each other as well as patients without any immune compromise.

Researchers also found that patients with severe immune compromise had a higher risk of developing resistance against COVID-fighting monoclonal antibodies.

“Providers and patients should be aware that protracted symptoms may mean persistent COVID-19 disease that requires additional testing and potential treatment,” Li said in a hospital news release.

Sources

  • Mass General Brigham, news release, Jan. 24, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Further Support and Information on COVID-19

Read this next

Extended Course of Paxlovid Adds No Benefit for Those With Long COVID

FRIDAY, June 7, 2024 -- An extended course of the antiviral drug Paxlovid won’t ease a person’s Long COVID symptoms, a new study finds. People who took Paxlovid for...

FDA Panel OKs New COVID Vaccine for Fall

THURSDAY, June 6, 2024 -- A U.S. Food and Drug Administration advisory panel on Wednesday recommended updating the formula for COVID vaccines ahead of a fall campaign that will...

Long COVID's Toll Outlined in New Report

THURSDAY, June 6, 2024 -- Long COVID continues to plague millions of Americans as the health costs of the pandemic linger four years later, a new report warns. In a hefty...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.